SG11202106129RA - Novel approach for treatment of cancer using immunomodulation - Google Patents

Novel approach for treatment of cancer using immunomodulation

Info

Publication number
SG11202106129RA
SG11202106129RA SG11202106129RA SG11202106129RA SG11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA
Authority
SG
Singapore
Prior art keywords
hhh hhh
hhh
talabostat
treatment
pembrolizumab
Prior art date
Application number
SG11202106129RA
Other languages
English (en)
Inventor
Vincent J O'neill
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of SG11202106129RA publication Critical patent/SG11202106129RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202106129RA 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation SG11202106129RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US201962924429P 2019-10-22 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
SG11202106129RA true SG11202106129RA (en) 2021-07-29

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106129RA SG11202106129RA (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Country Status (13)

Country Link
US (1) US20220089733A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893869A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512158A (cg-RX-API-DMAC7.html)
KR (1) KR20210102259A (cg-RX-API-DMAC7.html)
CN (1) CN113260361A (cg-RX-API-DMAC7.html)
AU (1) AU2019396206A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011205A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121270A1 (cg-RX-API-DMAC7.html)
IL (1) IL283742A (cg-RX-API-DMAC7.html)
MX (1) MX2021006778A (cg-RX-API-DMAC7.html)
SG (1) SG11202106129RA (cg-RX-API-DMAC7.html)
TW (1) TW202034955A (cg-RX-API-DMAC7.html)
WO (1) WO2020123496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
EP4099994A4 (en) * 2020-02-07 2024-02-14 OnkosXcel Therapeutics, LLC Treatment regimen for cancer using immunomodulation
WO2023154036A1 (en) * 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US20170369592A1 (en) * 2015-01-09 2017-12-28 Mabimmune Diagostics AG Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10954300B2 (en) * 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2018129497A1 (en) * 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
CA3121270A1 (en) 2020-06-18
JP2022512158A (ja) 2022-02-02
AU2019396206A1 (en) 2021-06-17
US20220089733A1 (en) 2022-03-24
CN113260361A (zh) 2021-08-13
JP2025156353A (ja) 2025-10-14
IL283742A (en) 2021-07-29
TW202034955A (zh) 2020-10-01
MX2021006778A (es) 2021-07-15
EP3893869A4 (en) 2022-08-17
BR112021011205A2 (pt) 2021-08-24
EP3893869A1 (en) 2021-10-20
WO2020123496A1 (en) 2020-06-18
KR20210102259A (ko) 2021-08-19

Similar Documents

Publication Publication Date Title
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
TW202346335A (zh) 治療al類澱粉變性症之方法
WO2023136837A1 (en) Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc)
EP4427751A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Wheatley et al. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Siu Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
HK40105135A (en) Combinations of cabozantinib and atezolizumab to treat cancer
TW202513098A (zh) 治療癌症之方法
Johnson Phase II Study of Durvalumab (MEDI4736)(anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer.
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment
Redmond Protocol Number: PHS IRB: 15-166
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Spillner Clinical Study Report (Synopsis)
Phaëton et al. SPONSOR SIGNATURE PAGE
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer